January 02, 2018
2 min read

WIN-TAVI: Mortality, stroke low in women 1 year after TAVR

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The incidence of mortality and stroke was low at 1 year in women at intermediate or high surgical risk who underwent transcatheter aortic valve replacement, according to new data from the WIN-TAVI registry.

As Cardiology Today’s Intervention previously reported, WIN-TAVI is the first all-female TAVR registry; 30-day outcomes were published in May 2016.

For the present analysis, Alaide Chieffo, MD, from the department of cardiology at San Raffaele Scientific Institute in Milan, and colleagues determined 1-year outcomes after TAVR in 1,019 intermediate- to high-risk women (mean age, 82 years; mean EuroSCORE I, 17.8%; mean Society of Thoracic Surgeons Predicted Risk of Mortality, 8.3%) from 18 European sites and one U.S. site.

The primary endpoint was 1-year Valve Academic Research Consortium (VARC-2) efficacy, defined as mortality, stroke, MI, hospitalization for valve-related symptoms, as well as HF or valve-related dysfunction beyond 30 days. The key secondary endpoint was death or stroke at 1 year.

The primary endpoint occurred in 10.9% of patients beyond 30 days and in 16.5% of patients at 1 year, Chieffo and colleagues wrote.

The rate of death or stroke at 1 year was 13.9%; death occurred in 12.5% and stroke in 2.2%, according to the researchers.

Independent predictors of the VARC-2 efficacy endpoint included prior coronary revascularization (HR = 1.72; 95% CI, 1.17-2.52) and EuroSCORE I (HR = 1.02; 95% CI, 1-1.04).

Independent predictors of death or stroke at 1 year included EuroSCORE I (HR = 1.02; 95% CI, 1-1.04), atrial fibrillation at baseline (HR = 1.58; 95% CI, 1.07-2.33) and previous PCI (HR = 1.5; 95% CI, 1.03-2.19), according to the researchers.

After adjustment, the researchers found no association between 1-year TAVR outcomes and history of pregnancy or any other sex-specific factors.

“Despite greater procedural complications, women demonstrate more favorable 1-year survival following TAVR compared with men, as a function of different baseline risks; lower prevalence of CAD, diabetes and AF; and higher baseline LVEF,” Chieffo and colleagues wrote. “In the current report we show that 1-year incidence of the VARC-2 efficacy endpoint was almost one-half the previously reported rates in prior TAVR studies with primarily older-generation devices.” – by Erik Swain

Disclosures: Chieffo reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.